

ASX Release

Anatara Investor Presentation

BRISBANE & MELBOURNE, 17th June 2019: Anatara Lifesciences (ASX:ANR) releases the presentation which Chief Executive Officer, Mr Steven Lydeamore, will present to investors in Perth this week and to the Gold Coast Investment Showcase later this month.

This presentation had been largely prepared prior to last week's announcement that animal health company, Zoetis had made a portfolio decision not to continue with the pursuit of Anatara's lead animal health asset, Detach[®]. To that end, while a new slide has been incorporated to reflect the current state of affairs with Detach[®], this presentation does not reflect the new commercialisation strategy for Detach[®], which Anatara's Board and Management team is closely reviewing over the coming weeks.

CEO, Steve Lydeamore commented, "We have been working hard this year to communicate with investors as transparently as possible regarding our progress. Continuing with our planned presentations in Perth and the Gold Coast this month is in keeping with our desire to communicate openly.

While the Board does not have all the answers regarding the future of the Detach[®] program at this stage, we are focused on determining the next steps in a timely manner and will communicate those as soon as practical in the coming weeks. In the meantime, we look forward to engaging with investors to discuss what we currently know and discuss the work we're doing in the area of human gastrointestinal health through our dietary supplement program."

Any shareholders with questions regarding Anatara's recent announcements or the attached investor presentation are invited to contact the company using the contact info below. Those investors wishing to attend the Gold Coast Investment Showcase are invited to register for complementary attendance [via this link](#).

For more information please contact:

Investor inquiries	Media inquiries
Mr Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Jane Lowe Managing Director, IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



Bringing Science to Supplements

June 2019



ANATARA
LIFESCIENCES

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Investor Message

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health



Key Financial Details

ASX Code ANR	Market Capitalisation ¹ \$9.9 million	Share Price ¹ \$0.20
Current Cash ² \$6.4 million	Ordinary Shares 49,413,236	Options 2,571,000

- ~\$1.25m **R&D tax refund** received for 2017-18 activities
- **Sufficiently funded** to execute on the development and partnering of our first human product



Company Highlights

- First animal product, Detach® - **approved** for use in piglets in Australia
- Key appointments with significant **human health experience**
 - Sue MacLeman, Dr Jane Ryan, Dr David Brookes, Steve Lydeamore
- First human product candidate
 - **Gastrointestinal ReProgramming (GaRP) dietary supplement** is aimed at restoring and maintaining **gut health**
 - Significant **unmet market need** for **IBS** and **IBD** patients
 - **World-leading scientists and clinicians** form our Product Development Advisory Board
 - **Successful *in vitro* proof of concept studies**
 - **18 – 24 months to partnering milestone**



Animal Health

- Detach® is a natural, safe, non-antibiotic product that **aids in the control of diarrhoea** (known as scour) in livestock
- In October 2018, the Australian Pesticides and Veterinary Medicines Authority (APVMA) **registered Detach® for use in piglets**
- Commercialisation opportunities under consideration following the announcement on 14 June 2019 that animal health company, Zoetis Inc would be returning rights for the product to Anantara
- Anantara had engaged with **>10 top** multi-national **animal health companies prior to licensing**. Board is reviewing next steps in Detach® strategy during coming weeks





From animals to humans



Market Opportunity

Irritable Bowel Syndrome (IBS)

Affects around **11%** of the global population⁴

~50% of patients⁵ turn to dietary supplements and complementary medicines

Low grade **inflammation**



Inflammatory Bowel Disease (IBD)

>5 million sufferers globally⁶

30-50% of IBD patients⁷ turn to complementary and alternative medicines



Chronic **inflammation**



Shared disease characteristics:

Altered microbiome
Impaired intestinal barrier function
Mucosal damage


Anatara's Unique Dietary Supplement - How does it work?



Scientifically Proven

Successful Proof of Concept Studies

- Potential breakthrough dietary product
- Anataara's proprietary GaRP formulation was⁹ efficacious and:
 - Reduced production of pro-inflammatory proteins by gut and inflammatory cells by >85%;



Reproduced from Gut 2010;59:1331e1339. doi:10.1136/gut.2009.195370

- Reduced the attachment and invasion of IBD and IBS pro-inflammatory bacteria into healthy gut cells by >95%;
- Protected and maintained gut integrity.



Advantages of Dietary Supplements*

The advantages of a dietary supplement regulatory strategy are:


Fewer or lower regulatory requirements than pharmaceuticals¹⁰

- Lower development cost
- Lower development risk
- Faster time to market

Rapid market penetration¹¹

Public and health care professionals understand the term 'dietary supplement'

Marketing can be aimed at both the public and the professional



* Dietary Supplement are foods intended to supplement the normal diet which are concentrated sources of one or more nutrients, like vitamins, proteins, mineral complexes, herb or other botanical, amino acid or enzymes.

Clear Path to Commercialisation

	2017 H1	2017 H2	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
Confirmed GRAS status for components with FDA	✓							
Established collaboration with University of Liverpool (UK)		✓						
Completed product development plan		✓						
Patent Application filed				✓				
Commercial feasibility			✓					
Manufacturing – sourced suppliers		✓						
Proof of concept				✓				
Animal study (IBD)						F*		
Human clinical study (IBS)						S*		
Partnering discussions								F*

* Finish; Start



Anatara Lifesciences Ltd (ASX:ANR) Summary

- Innovative, evidence-based products, backed by scientific and clinical studies for gastrointestinal health
- GaRP dietary supplement seeks to target IBS and IBD patients
 - Patentable multi-component, dual-targeted formulation
 - Delivers the components where they can be most effective
- Board and Management have significant deal experience
- 18 – 24 months to partnering milestone



Steven Lydeamore, CEO
slydeamore@anatara.com

www.anataralifesciences.com



@AnataraANR



ANATARA LIFESCIENCES

